{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:06:34Z","timestamp":1779062794231,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The present study was supported by 2023 Government-funded Clinical Medicine Talent Training Project","award":["NO: ZF2023104"],"award-info":[{"award-number":["NO: ZF2023104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Framingham Steatosis Index (FSI) is a validated surrogate marker of hepatic steatosis and metabolic dysfunction. Emerging evidence suggests that metabolic abnormalities and accelerated biological aging may contribute to osteoarthritis (OA). However, whether FSI is associated with OA and whether this relationship is mediated by Phenotypic Age (PhenoAge) remain unclear. This study conducted a cross-sectional analysis of 9279 U.S. adults from the National Health and Nutrition Examination Survey, including 948 participants with OA. Weighted logistic regression models were applied to evaluate the association between FSI and OA. Restricted cubic splines and two-piecewise linear regression were used to assess nonlinear relationships and threshold effects. Subgroup analyses were performed to examine effect modification. Exploratory mediation analysis was conducted to quantify the mediating role of PhenoAge in the FSI\u2013OA relationship. Higher FSI was significantly associated with OA (Model 3: OR\u2009=\u20091.18, 95% CI 1.12\u20131.25,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), with a clear dose\u2013response pattern across quartiles (\n                    <jats:italic>p<\/jats:italic>\n                    for trend\u2009&lt;\u20090.001). A nonlinear association was observed with an inflection at FSI\u2009=\u2009\u2013\u00a01.798; OA prevalence increased steeply below this threshold. Subgroup analyses showed consistent positive associations across strata. Exploratory mediation analysis suggested that PhenoAge may partially account for this association between FSI and OA, accounting for 23.03% of the total effect. FSI was positively associated with OA prevalence in U.S. adults, and Phenotypic Age may partially account for this association. Future longitudinal studies are needed to clarify causality and determine whether improving metabolic health or slowing biological aging can reduce OA risk.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-45922-2","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:21:10Z","timestamp":1775024470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the Framingham steatosis index and osteoarthritis: evidence of mediation by phenotypic age"],"prefix":"10.1038","volume":"16","author":[{"given":"Tianhao","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"45922_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx6649","author":"M Singla","year":"2025","unstructured":"Singla, M. et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science https:\/\/doi.org\/10.1126\/science.adx6649 (2025).","journal-title":"Science"},{"key":"45922_CR2","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol 5, e508\u2013e522. https:\/\/doi.org\/10.1016\/s2665-9913(23)00163-7 (2023).","DOI":"10.1016\/s2665-9913(23)00163-7"},{"key":"45922_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nrrheum.2016.136","volume":"12","author":"WH Robinson","year":"2016","unstructured":"Robinson, W. H. et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 580\u2013592. https:\/\/doi.org\/10.1038\/nrrheum.2016.136 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"45922_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00301-9","volume":"11","author":"G Wei","year":"2023","unstructured":"Wei, G. et al. Risk of metabolic abnormalities in osteoarthritis: A new perspective to understand its pathological mechanisms. Bone Res. 11, 63. https:\/\/doi.org\/10.1038\/s41413-023-00301-9 (2023).","journal-title":"Bone Res."},{"key":"45922_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrrheum.2012.135","volume":"8","author":"Q Zhuo","year":"2012","unstructured":"Zhuo, Q., Yang, W., Chen, J. & Wang, Y. Metabolic syndrome meets osteoarthritis. Nat. Rev. Rheumatol. 8, 729\u2013737. https:\/\/doi.org\/10.1038\/nrrheum.2012.135 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"45922_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2025.101361","volume":"103","author":"D Kim","year":"2025","unstructured":"Kim, D. et al. Implications of obesity-mediated cellular dysfunction and adipocytokine signaling pathways in the pathogenesis of osteoarthritis. Mol. Aspects Med. 103, 101361. https:\/\/doi.org\/10.1016\/j.mam.2025.101361 (2025).","journal-title":"Mol. Aspects Med."},{"key":"45922_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2018.10.002","volume":"44","author":"T Wang","year":"2018","unstructured":"Wang, T. & He, C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 44, 38\u201350. https:\/\/doi.org\/10.1016\/j.cytogfr.2018.10.002 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"45922_CR8","doi-asserted-by":"publisher","first-page":"20711","DOI":"10.1021\/acsnano.5c02515","volume":"19","author":"MY Li","year":"2025","unstructured":"Li, M. Y. et al. Biomimetic liposomes for G-protein-coupled receptor 120 exo\/endogenous coactivation to reprogram lipid metabolism in obesity-associated osteoarthritis. ACS Nano 19, 20711\u201320728. https:\/\/doi.org\/10.1021\/acsnano.5c02515 (2025).","journal-title":"ACS Nano"},{"key":"45922_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021096118","author":"KH Collins","year":"2021","unstructured":"Collins, K. H. et al. Adipose tissue is a critical regulator of osteoarthritis. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2021096118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45922_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-024-01143-3","volume":"20","author":"M Binvignat","year":"2024","unstructured":"Binvignat, M., Sellam, J., Berenbaum, F. & Felson, D. T. The role of obesity and adipose tissue dysfunction in osteoarthritis pain. Nat. Rev. Rheumatol. 20, 565\u2013584. https:\/\/doi.org\/10.1038\/s41584-024-01143-3 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"45922_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001608","author":"MB Bansal","year":"2025","unstructured":"Bansal, M. B. et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology https:\/\/doi.org\/10.1097\/hep.0000000000001608 (2025).","journal-title":"Hepatology"},{"key":"45922_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01197-7","author":"CH Liu","year":"2025","unstructured":"Liu, C. H. et al. Sarcopenia and MASLD: Novel insights and the future. Nat. Rev. Endocrinol. https:\/\/doi.org\/10.1038\/s41574-025-01197-7 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"45922_CR13","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1007\/s11357-025-01816-1","volume":"47","author":"M Del Rio-Moreno","year":"2025","unstructured":"Del Rio-Moreno, M. et al. Liver injury severity determines skeletal deterioration: A shared pathophysiological axis between MASLD and osteoarthritis. Geroscience 47, 6439\u20136454. https:\/\/doi.org\/10.1007\/s11357-025-01816-1 (2025).","journal-title":"Geroscience"},{"key":"45922_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03272-2","volume":"26","author":"Y Lu","year":"2024","unstructured":"Lu, Y., Zhang, J., Li, H. & Li, T. Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults. Arthritis Res. Ther. 26, 40. https:\/\/doi.org\/10.1186\/s13075-024-03272-2 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"45922_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","volume":"14","author":"MT Long","year":"2016","unstructured":"Long, M. T. et al. Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis. Clin. Gastroenterol. Hepatol. 14, 1172-1180.e1172. https:\/\/doi.org\/10.1016\/j.cgh.2016.03.034 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"45922_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000044800","volume":"104","author":"F Yang","year":"2025","unstructured":"Yang, F., Gao, X., Tang, R. & Yang, K. The Framingham steatosis index as a predictor of advanced CKM syndrome in US adults: Evidence from NHANES 2001 to 2018. Medicine 104, e44800. https:\/\/doi.org\/10.1097\/md.0000000000044800 (2025).","journal-title":"Medicine"},{"key":"45922_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0337104","volume":"20","author":"D Huang","year":"2025","unstructured":"Huang, D., Zou, H. & Zhang, Y. Association of Framingham steatosis index with albuminuria: A cross-sectional study. PLoS ONE 20, e0337104. https:\/\/doi.org\/10.1371\/journal.pone.0337104 (2025).","journal-title":"PLoS ONE"},{"key":"45922_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.18632\/aging.101414","volume":"10","author":"ME Levine","year":"2018","unstructured":"Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging 10, 573\u2013591. https:\/\/doi.org\/10.18632\/aging.101414 (2018).","journal-title":"Aging"},{"key":"45922_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02855-w","volume":"24","author":"Z Zeng","year":"2025","unstructured":"Zeng, Z. et al. Biological aging and incident cardiovascular diseases in individuals with diabetes: Insights from a large prospective cohort study. Cardiovasc. Diabetol. 24, 320. https:\/\/doi.org\/10.1186\/s12933-025-02855-w (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"45922_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13073-024-01403-7","volume":"16","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Exploring multi-omics and clinical characteristics linked to accelerated biological aging in Asian women of reproductive age: Insights from the S-PRESTO study. Genome Med. 16, 128. https:\/\/doi.org\/10.1186\/s13073-024-01403-7 (2024).","journal-title":"Genome Med."},{"key":"45922_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/27697061.2024.2389398","volume":"44","author":"Q He","year":"2025","unstructured":"He, Q. et al. The relationship between central obesity and osteoarthritis in US adults: The mediating role of biological aging acceleration. J. Am. Nutr. Assoc. 44, 29\u201339. https:\/\/doi.org\/10.1080\/27697061.2024.2389398 (2025).","journal-title":"J. Am. Nutr. Assoc."},{"key":"45922_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80151-5","volume":"14","author":"X Li","year":"2024","unstructured":"Li, X. et al. Relationship between weight-adjusted waist index (WWI) and osteoarthritis: A cross-sectional study using NHANES data. Sci. Rep. 14, 28554. https:\/\/doi.org\/10.1038\/s41598-024-80151-5 (2024).","journal-title":"Sci. Rep."},{"key":"45922_CR23","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1210\/clinem\/dgab415","volume":"106","author":"KA MacGregor","year":"2021","unstructured":"MacGregor, K. A., Gallagher, I. J. & Moran, C. N. Relationship between insulin sensitivity and menstrual cycle is modified by BMI, fitness, and physical activity in NHANES. J. Clin. Endocrinol. Metab. 106, 2979\u20132990. https:\/\/doi.org\/10.1210\/clinem\/dgab415 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"45922_CR24","doi-asserted-by":"publisher","unstructured":"Han, A. & Kim, Y. Association Between Non-Alcoholic Fatty Liver Disease and Osteoarthritis. https:\/\/doi.org\/10.21203\/rs.3.rs-555647\/v1 (2021).","DOI":"10.21203\/rs.3.rs-555647\/v1"},{"issue":"2","key":"45922_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.21037\/hbsn.2018.11.11","volume":"8","author":"L Pacifico","year":"2019","unstructured":"Pacifico, L., Perla, F. & Chiesa, C. Sarcopenia and nonalcoholic fatty liver disease: A causal relationship. Hepatobiliary Surg. Nutr. 8(2), 144\u2013147. https:\/\/doi.org\/10.21037\/hbsn.2018.11.11 (2019).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"45922_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098445","author":"O Drapkina","year":"2023","unstructured":"Drapkina, O., Elkina, A. Y., Sheptulina, A. & Kiselev, A. Non-alcoholic fatty liver disease and bone tissue metabolism: Current findings and future perspectives. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24098445 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"45922_CR27","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s42255-025-01394-8","volume":"7","author":"RM Mancina","year":"2025","unstructured":"Mancina, R. M., Valenti, L. & Romeo, S. Human genetics of steatotic liver disease: Insights into insulin resistance and lipid metabolism. Nat. Metab. 7, 2199\u20132211. https:\/\/doi.org\/10.1038\/s42255-025-01394-8 (2025).","journal-title":"Nat. Metab."},{"key":"45922_CR28","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard, A. T. et al. Target populations for novel triglyceride-lowering therapies. J. Am. Coll. Cardiol. 85, 1876\u20131897. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.035 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"45922_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s12072-024-10698-y","volume":"18","author":"R Gish","year":"2024","unstructured":"Gish, R. et al. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatol. Int. 18, 977\u2013989. https:\/\/doi.org\/10.1007\/s12072-024-10698-y (2024).","journal-title":"Hepatol. Int."},{"key":"45922_CR30","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.7150\/ijbs.117211","volume":"21","author":"M Kang","year":"2025","unstructured":"Kang, M. et al. Pathophysiology, development, and mortality of major non-communicable diseases in metabolic dysfunction-associated steatotic liver disease: A comprehensive review. Int. J. Biol. Sci. 21, 5691\u20135703. https:\/\/doi.org\/10.7150\/ijbs.117211 (2025).","journal-title":"Int. J. Biol. Sci."},{"key":"45922_CR31","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/art.38399","volume":"66","author":"O Alvarez-Garcia","year":"2014","unstructured":"Alvarez-Garcia, O., Rogers, N. H., Smith, R. G. & Lotz, M. K. Palmitate has proapoptotic and proinflammatory effects on articular cartilage and synergizes with interleukin-1. Arthr. Rheumatol. 66, 1779\u20131788. https:\/\/doi.org\/10.1002\/art.38399 (2014).","journal-title":"Arthr. Rheumatol."},{"key":"45922_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s13679-023-00520-5","volume":"12","author":"SJP Sampath","year":"2023","unstructured":"Sampath, S. J. P., Venkatesan, V., Ghosh, S. & Kotikalapudi, N. Obesity, metabolic syndrome, and osteoarthritis-an updated review. Curr. Obes. Rep. 12, 308\u2013331. https:\/\/doi.org\/10.1007\/s13679-023-00520-5 (2023).","journal-title":"Curr. Obes. Rep."},{"key":"45922_CR33","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s12276-021-00697-6","volume":"53","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Hyperglycemia-induced accumulation of advanced glycosylation end products in fibroblast-like synoviocytes promotes knee osteoarthritis. Exp. Mol. Med. 53, 1735\u20131747. https:\/\/doi.org\/10.1038\/s12276-021-00697-6 (2021).","journal-title":"Exp. Mol. Med."},{"key":"45922_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116978","volume":"238","author":"F Jiaxin","year":"2025","unstructured":"Jiaxin, F. et al. Metformin exhibits inhibitory effects on ferroptosis and alleviates chondrocyte metabolic imbalance in osteoarthritis models, as well as Erastin-induced ferroptosis, through the modulation of the P53\/SLC7A11 pathway. Biochem. Pharmacol. 238, 116978. https:\/\/doi.org\/10.1016\/j.bcp.2025.116978 (2025).","journal-title":"Biochem. Pharmacol."},{"key":"45922_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.952560","volume":"13","author":"Y Song","year":"2022","unstructured":"Song, Y., Wu, Z. & Zhao, P. The effects of metformin in the treatment of osteoarthritis: Current perspectives. Front. Pharmacol. 13, 952560. https:\/\/doi.org\/10.3389\/fphar.2022.952560 (2022).","journal-title":"Front. Pharmacol."},{"key":"45922_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/acel.12562","volume":"16","author":"K McCulloch","year":"2017","unstructured":"McCulloch, K., Litherland, G. J. & Rai, T. S. Cellular senescence in osteoarthritis pathology. Aging Cell 16, 210\u2013218. https:\/\/doi.org\/10.1111\/acel.12562 (2017).","journal-title":"Aging Cell"},{"key":"45922_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410795","volume":"12","author":"X Zhao","year":"2025","unstructured":"Zhao, X. et al. Targeting p21-positive senescent chondrocytes via IL-6R\/JAK2 inhibition to alleviate osteoarthritis. Adv. Sci. 12, e2410795. https:\/\/doi.org\/10.1002\/advs.202410795 (2025).","journal-title":"Adv. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45922-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:33:51Z","timestamp":1779060831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45922"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45922-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The National Health and Nutrition Examination Survey (NHANES) is an ongoing, large-scale cross-sectional survey conducted in the United States to provide objective health data and address emerging public health challenges in the general population. All participants in NHANES provided consent for their data to be used in the study. The present analysis was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Data collection for the NHANES was approved by the NCHS Research Ethics Review Board (ERB). An individual investigator using the publicly available NHANES data does not need to file with the institutional review board (IRB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"15304"}}